BioAge Therapeutics
BioAge Therapeutics Raises $350M Series C to Transform Healthcare
Quick Facts
BioAge Therapeutics
Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.
About the Funding
BioAge Therapeutics has successfully raised $350M in a Series C funding round, bringing their total valuation to $4.3B. This significant investment will fuel the company's mission to advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies.
Use of Funds
Advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies
Company Overview
Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.
Key Investors
- • Genentech Ventures
- • Gilead Sciences
- • Andreessen Horowitz Bio Fund
- • Jeff Bezos
Founders
- • Dr. Sarah Longevity
- • Dr. James Youth
Previous Rounds
Market Impact
This funding round positions BioAge Therapeutics as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza